OpenEvidence
OpenEvidence builds an AI search and decision-support platform for clinicians, grounded in medical evidence.
The Company
OpenEvidence builds an AI platform that helps clinicians find and synthesize medical evidence at the point of care.
It raised a $250 million Series D at a $12 billion valuation in January 2026, doubling the valuation reported at its preceding round.
Why It Matters
Clinical AI is a high-stakes category where product quality, evidence partnerships, and workflow adoption matter as much as model capability. OpenEvidence is a key private-market signal for trusted, vertical AI distribution.
Valuation History
What Changed
Announced $250M Series D at a $12B valuation.
THE NEXT COMPANY. A CLEARER PICTURE.
Get the next breakdown.
Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.